论文部分内容阅读
目的研究分析小剂量递增服用厄贝沙坦联合普萘洛尔防治肝硬化门脉高压的临床效果及应用价值。方法 70例肝硬化门脉高压患者依据使用药物不同分为观察组(24例)与对照1组(23例)、对照2组(23例),分别采用厄贝沙坦+普萘洛尔、厄贝沙坦、普萘洛尔治疗,并检测其相关指标。结果三组患者治疗后丙氨酸转氨酶(ALT)等肝功能指标得到均明显改善(P<0.05),且观察组ALT(36.24±9.13)U/L等肝功能指标改善均优于对照1组(47.29±10.34)U/L、对照2组(47.18±9.89)U/L(P<0.05),而对照1组与对照2组治疗后ALT等肝功能指标比较,差异无统计学意义(P>0.05)。三组患者治疗后静脉内径及平均血流速度均明显改善,且观察组明显优于其他两组(P<0.05)。结论采用小剂量递增服用厄贝沙坦联合普萘洛尔对肝硬化门脉高压的治疗具有较大效果,值得临床推广。
Objective To study the clinical effects and application value of irbesartan combined with propranolol in preventing and treating cirrhosis and portal hypertension with small dose escalation. Methods Seventy patients with cirrhosis and portal hypertension were divided into observation group (24 cases) and control group (23 cases) and control group (23 cases) according to different drugs. The patients were treated with irbesartan and propranolol, Irbesartan, propranolol treatment, and test the relevant indicators. Results The liver function indexes of alanine aminotransferase (ALT) were significantly improved after treatment in all three groups (P <0.05), and the ALT (36.24 ± 9.13) U / L in the observation group was better than the control group 1 (47.29 ± 10.34) U / L, and control group 2 (47.18 ± 9.89) U / L (P <0.05). There was no significant difference in ALT and other liver function indexes between the control group 1 and the control group 2 > 0.05). Three groups of patients after treatment, intravenous diameter and mean velocity were significantly improved, and the observation group was significantly better than the other two groups (P <0.05). Conclusion Adopting small dose escalation of irbesartan and propranolol has a great effect on the treatment of cirrhosis and portal hypertension, which is worthy of clinical promotion.